How does rofecoxib (a COX-2 inhibitor) affect the stomach lining?
Rofecoxib selectively inhibits COX-2, which lowers production of prostaglandins involved in pain and inflammation. The stomach lining depends on a different set of prostaglandins—made largely through COX-1—to help maintain protective functions such as mucus and bicarbonate secretion and adequate blood flow to the mucosa. Because rofecoxib leaves COX-1 activity comparatively more intact than nonselective NSAIDs, it was expected to cause fewer stomach and intestinal ulcers in many patients. However, COX-2 inhibition can still disturb the balance of protective and inflammatory prostaglandins in the gut, so risk is not eliminated.
Why can COX-2 inhibition still cause ulcers or gastritis?
Even though COX-1 is the main driver of gastric protection, COX-2 also contributes to prostaglandin signaling in the gastrointestinal tract. When COX-2 is inhibited, the stomach and upper GI tract may have less ability to respond to injury and maintain local repair processes. That means rofecoxib can still increase gastrointestinal adverse effects, especially with higher doses, longer use, or in people already at higher risk for ulcer disease.
How does rofecoxib differ from traditional NSAIDs like ibuprofen or naproxen?
Nonselective NSAIDs inhibit both COX-1 and COX-2. By blocking COX-1, they reduce the prostaglandins that protect the stomach lining, which tends to raise the risk of dyspepsia, erosions, and bleeding ulcers. A COX-2-selective drug like rofecoxib generally spares COX-1 more, so it often has a lower ulcer/bleeding risk than nonselective NSAIDs, but it can still cause GI harm through its effects on COX-2–linked prostaglandin pathways.
What factors make stomach injury more likely with rofecoxib?
Risk tends to rise when there are additional “hits” to the GI lining and repair system, such as:
- Higher doses or longer duration
- Prior history of ulcers or GI bleeding
- Concurrent use of other ulcer-risk medications (for example, aspirin or corticosteroids)
- Older age and serious comorbid illness
What symptoms might patients notice?
People may develop upper-GI symptoms that can reflect irritation or evolving ulcer disease, including stomach pain or burning, indigestion, nausea, and heartburn. Severe complications include GI bleeding, which may present as black/tarry stools, vomiting blood, or sudden weakness/lightheadedness.
Where does the science stop without more detail?
Your question asks specifically how rofecoxib’s COX-2 inhibition affects the stomach lining. The key mechanistic idea is that gastric protection relies heavily on COX-1–derived prostaglandins, while COX-2 also participates in GI mucosal protection and repair. COX-2 inhibition therefore reduces protective prostaglandin signaling enough to still raise GI risk, even though it may be less than nonselective NSAIDs.
If you share whether you mean “increased ulcer risk,” “mechanism of mucosal injury,” or “what the clinical trials showed,” I can tailor the explanation to that angle.